Archives

Archive for November, 2013

a retrospective rebate and turkey…

Glaxo Sparks Fury Over Sign-On Bonus Demand Sky News By Mark Kleinman 28 November 2013 GlaxoSmithKline [GSK], Britain’s biggest drugs company, has sparked fury among some of its biggest suppliers by demanding ‘bonus’ payments to continue working with the group. Sky News understands that GSK has asked hundreds of marketing services agencies to agree to […]

graphic reflections…

[click for source] hat tip to jamzo…   I don’t really know anything about patents and drug exclusivity in the UK. I presume it’s somewhat similar to the US [on the left][if that’s wrong, someone let me know]. The upper graph is number of prescriptions and the bottom graph is overall cost. I thought it was […]

by definition…

If I’m not a cardiologist and only an Internist in memory, why does this Statin thing get my juices flowing so [an exempler…, but I should’ve…, risk benefit ratio…]? I know there are people who are going to  take Statins for the same reason a lot of people go to church ["just in case"]. I […]

for a good year…

Happy Thanksgiving

risk benefit ratio…

( OPINION )

I appreciate Peggi’s recent comment on the blogs about Statins [an exempler…, but I should’ve…]. It highlights the subjective but central issue of the risk·benefit ratio: When one is trying simply to be an informed patient and has become aware of all this corruption and COI in so many aspects of medicine, how on earth […]

as for idealism…

I think, by nature, I might be an idealist – someone who thinks that right will prevail sooner or later. I never really thought that, but it seems to be true. Watching what happened in psychiatry in the 80s didn’t fit for me personally, but I thought things would strike a balance sooner or later. […]

but I should’ve…

I sort of stepped out of my usual box talking about the Statins [and here I go again]. They are a bit like many of our psychiatric drugs in that they’re optional, but they differ in that they’re focused on a measurable biologic marker [serum lipids]. In an exempler…, I talked about objecting to massive […]

a major force…

( OPINION )

“I call psychiatry the drug industry’s paradise.” Peter Gøtzsche Peter C Gøtzsche Director of The Nordic Cochrane Centre Professor Peter C Gøtzsche graduated with a Master of Science in biology and chemistry in 1974 and as a physician in 1984. He is a specialist in internal medicine; worked with clinical trials and regulatory affairs in […]

an exempler…

( OPINION )

I’ve been otherwise occupied, and not so vigilant as usual about the things I usually follow. Catching up, there’s aplenty to report, but this particular issue has an emotional valence for me from a long time ago – at least forty years. It has to do with small differences in medicine: Should people at low […]

careful watching…

Failure to Report Financial Disclosure Information ONLINE FIRST by Robert D. Gibbons, PhD; David J. Weiss, PhD; Paul A. Pilkonis, PhD; Ellen Frank, PhD; and David J. Kupfer, MD JAMA Psychiatry. Published online November 20, 2013. To the Editor We apologize to the editors and readers of JAMA Psychiatry for our failure to fully disclose our financial interests in an article that reported a diagnostic tool, […]